持续高水平的凝血因子XI作为静脉血栓形成的危险因素
Luca Spiezia1, Chiara Forestan1, Elena Campello1
1General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, University of Padova, 35138 Padova, Italy.
Journal of clinical medicine
|August 12, 2023
概括
持续高水平的凝血因子XI (FXI) 显著增加深静脉血栓症 (DVT) 的风险. 监测FXI可能有助于识别患血栓事件风险较高的个体.
科学领域:
- 血液学 血液学 血液学
- 血栓形成研究研究
- 血管医学 血管医学
背景情况:
- 凝血因子XI (FXI) 在纤维素形成中起作用,并抑制纤维素分解.
- 在单次测量中发现的高血FXI水平与血栓形成风险增加有关.
研究的目的:
- 调查持续升高的血FXI水平与深静脉血栓塞 (DVT) 风险之间的关联.
主要方法:
- 一项涉及患者的病例控制研究,评估了近端下肢DVT的第一个发作.
- 血FXI水平在抗凝固后至少一个月 (T1) 测量,并在三个月后 (T2) 测量高水平 (>第90百分位) 的患者.
主要成果:
- 在200名患者中,47名患者在T1时呈现高水平的FXI,16名患者在T2时呈现持续高水平的FXI.
- 在T1时FXI升高的患者对DVT的调整几率比为2.4 (p < 0.001).
- 在T2持续高的FXI水平与明显更高的DVT风险相关,赔率比为5.2 (p < 0.001).
结论:
- 升高的FXI水平是DVT的危险因素.
- 持续高的FXI水平几乎使得DVT的风险增加了一倍.
- 需要进一步的前性研究来验证这些发现.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Disorders of Hemostasis
991
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
991
Extrinsic and Intrinsic Pathways of Hemostasis
8.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.3K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


